SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Condition(s) studied

Investigational drug(s) / intervention(s)

SGLT2 inhibitor: Patients started on SGLT2 inhibitors after PCI for AMI

Study summary

Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction.

The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.

Eligibility

Primary outcome measure(s)

• Major adverse cardiac and cerebrovascular events — 2 years
  A composite of cardiac death, nonfatal MI, nonfatal stroke, and HF hospitalization

Trial sites (1)

Other trials for the same condition